GSK plc 6-K, filed Apr 14, 2025
GSK plc (GSK)
6-K
2025-04-14
For: 2025-04-14
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on April 14, 2025.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of April 2025
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the
'Company')
Transaction
notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Elizabeth
McKee Anderson
|
|||
|
b)
|
Position/status
|
Independent
Non-Executive Director
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 10 April 2025
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$34.1210
|
26
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date of
the transaction
|
2025-04-11
|
|||
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Charles
Bancroft
|
|||
|
b)
|
Position/status
|
Senior
Independent Non-Executive Director
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 10 April 2025
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$34.1210
|
174
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date of
the transaction
|
2025-04-11
|
|||
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Dr Hal
Barron
|
|||
|
b)
|
Position/status
|
Non-Executive
Director
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 10 April 2025
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$34.1210
|
29
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date of
the transaction
|
2025-04-11
|
|||
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Dr Anne
Beal
|
|||
|
b)
|
Position/status
|
Independent
Non-Executive Director
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 10 April 2025
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$34.1210
|
22
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date of
the transaction
|
2025-04-11
|
|||
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Dr
Harry Dietz
|
|||
|
b)
|
Position/status
|
Independent
Non-Executive Director
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 10 April 2025
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$34.1210
|
22
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date of
the transaction
|
2025-04-11
|
|||
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Dr
Jesse Goodman
|
|||
|
b)
|
Position/status
|
Independent
Non-Executive Director
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 10 April 2025
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$34.1210
|
22
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date of
the transaction
|
2025-04-11
|
|||
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Dr
Jeannie Lee
|
|||
|
b)
|
Position/status
|
Independent
Non-Executive Director
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 10 April 2025
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$34.1210
|
10
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date of
the transaction
|
2025-04-11
|
|||
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Dr
Vishal Sikka
|
|||
|
b)
|
Position/status
|
Independent
Non-Executive Director
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
American
Depositary Shares ('ADSs')
ISIN:
US37733W2044
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition
of ADSs following the re-investment of dividends paid to
shareholders on 10 April 2025
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$34.1210
|
98
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date of
the transaction
|
2025-04-11
|
|||
|
f)
|
Place
of the transaction
|
New
York Stock Exchange (XNYS)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Emma
Walmsley
|
|||
|
b)
|
Position/status
|
Chief
Executive Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 10 April 2025.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.0668
|
4,560.318
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date of
the transaction
|
2025-04-10
|
|||
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Diana
Conrad
|
|||
|
b)
|
Position/status
|
Chief
People Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 10 April 2025.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.0668
|
1,512.439
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date of
the transaction
|
2025-04-10
|
|||
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
James
Ford
|
|||
|
b)
|
Position/status
|
SVP and
Group General Counsel, Legal and Compliance
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 10 April 2025.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.0668
|
2,662.666
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date of
the transaction
|
2025-04-10
|
|||
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Sally
Jackson
|
|||
|
b)
|
Position/status
|
SVP,
Global Communications and CEO Office
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 10 April 2025.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.0668
|
945.209
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date of
the transaction
|
2025-04-10
|
|||
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Dylan
Jackson
|
|||
|
b)
|
Position/status
|
PCA
of Sally Jackson (SVP, Global Communications and CEO
Office)
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 10 April 2025.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.0668
|
171.965
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date of
the transaction
|
2025-04-10
|
|||
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Luke
Miels
|
|||
|
b)
|
Position/status
|
Chief
Commercial Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 10 April 2025.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.0668
|
12,698.763
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date of
the transaction
|
2025-04-10
|
|||
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
David
Redfern
|
|||
|
b)
|
Position/status
|
President
Corporate Development
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 10 April 2025.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.0668
|
7,700.043
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date of
the transaction
|
2025-04-10
|
|||
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Regis
Simard
|
|||
|
b)
|
Position/status
|
President, Global
Supply Chain
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 10 April 2025.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.0668
|
3,208.918
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date of
the transaction
|
2025-04-10
|
|||
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Philip
Thomson
|
|||
|
b)
|
Position/status
|
President,
Global Affairs
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 10 April 2025.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.0668
|
2,630.473
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date of
the transaction
|
2025-04-10
|
|||
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Kate
Thomson
|
|||
|
b)
|
Position/status
|
PCA of
Philip Thomson (President, Global Affairs)
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 10 April 2025.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.0668
|
134.156
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date of
the transaction
|
2025-04-10
|
|||
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Deborah
Waterhouse
|
|||
|
b)
|
Position/status
|
CEO,
ViiV Healthcare and President, Global Health, GSK
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 10 April 2025.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.0668
|
1,569.323
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date of
the transaction
|
2025-04-10
|
|||
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Tony
Wood
|
|||
|
b)
|
Position/status
|
Chief
Scientific Officer
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN:
GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 10 April 2025.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.0668
|
1,558.013
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date of
the transaction
|
2025-04-10
|
|||
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|||
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||||
|
a)
|
Name
|
Victoria
Whyte
|
|||
|
b)
|
Position/status
|
Company
Secretary
|
|||
|
c)
|
Initial
notification/amendment
|
Initial
notification
|
|||
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
GSK
plc
|
|||
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|||
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||||
|
a)
|
Description
of the financial instrument
|
Ordinary
shares of 31 ¼ pence each ('Ordinary Shares')
ISIN: GB00BN7SWP63
|
|||
|
b)
|
Nature
of the transaction
|
Acquisition
of Ordinary Shares following the re-investment of dividends paid to
shareholders on 10 April 2025.
|
|||
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£13.0668
|
135.011
|
|
||
|
|
|
|
|
||
|
d)
|
Aggregated
information
|
N/A
(single transaction)
|
|||
|
Aggregated
volume Price
|
|
||||
|
e)
|
Date of
the transaction
|
2025-04-10
|
|||
|
f)
|
Place
of the transaction
|
London
Stock Exchange (XLON)
|
|||
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: April
14, 2025
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|